ECGI in Patients With Persistent Atrial Fibrillation

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

January 1, 2022

Study Completion Date

April 1, 2022

Conditions
Atrial Fibrillation
Interventions
PROCEDURE

Radiofrequency ablation

RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).

Trial Locations (1)

Unknown

Bumrungrad International Hospital, Bangkok

All Listed Sponsors
lead

Pacific Rim Electrophysiology Research Institute

OTHER

NCT03836092 - ECGI in Patients With Persistent Atrial Fibrillation | Biotech Hunter | Biotech Hunter